OZEM
Roundhill GLP-1 & Weight Loss ETF·NASDAQ
--
--(--)
--
--(--)
Key Stats
Assets Under Management
58.08MUSD
Fund Flows (1Y)
5.33MUSD
Dividend Yield
1.17%
Discount/Premium to NAV
-0.30%
Shares Outstanding
1.67M
Expense Ratio
0.59%
About Roundhill GLP-1 & Weight Loss ETF
Issuer
Roundhill Financial Inc.
Brand
Roundhill
Inception Date
May 21, 2024
Structure
Open-Ended Fund
Index Tracked
--
Management Style
Active
Dividend Treatment
Distributes
Distribution Tax Treatment
Qualified dividends
Income Tax Type
Capital Gains
Max ST Capital Gains Rate
39.60%
Max LT Capital Gains Rate
20.00%
Primary Advisor
Roundhill Financial, Inc.
Distributor
Foreside Fund Services LLC
OZEM targets the global weight management industry. The fund invests in companies involved in the development of GLP-1 and other weight loss drugs. GLP-1 agonists seek to aid in weight management by lowering blood sugar levels, reducing appetite, and promoting fullness. The portfolio consists of firms with GLP-1 and weight loss drugs that have been approved by or are currently undergoing Phase I, Phase II, and/or Phase III clinical trials of the US Food & Drug Administration (FDA), or any applicable food and drug regulator for non-US companies. The portfolio is constructed using a proprietary methodology, which selects companies with high levels of thematic relevance based on research of each company's public filings and disclosures. In addition, eligible securities must meet minimum market-cap and liquidity requirements. The actively managed fund, although rebalances portfolio weighting on at least a quarterly basis, may have a heavy concentration on a few names.
Classification
Asset Class
Equity
Category
Sector
Focus
Health Care
Niche
Pharma, Biotech & Life Sciences
Strategy
Active
Geography
--
Weighting Scheme
Proprietary
Selection Criteria
Proprietary
Returns
1-Month | 3-Month | YTD | 1-Year | 3-Year | 5-Year | |
|---|---|---|---|---|---|---|
Price Performance | -0.20% | +18.64% | +1.10% | +38.67% | +37.85% | +37.85% |
NAV Total Return | -3.25% | +14.97% | -2.37% | +33.43% | -0.01% | -0.01% |
Ratings
No data is currently available
Ainvest’s AI-powered ETF Scoring Algorithm, built to help retail investors make smarter, data-driven decisions. Leveraging deep learning, reinforcement learning, and large language models, the algorithm scores ETFs across five key dimensions: Fund Flow, Momentum, Safety, Fundamentals, and Performance. Each factor is weighted by its correlation to future returns, resulting in a single, actionable score. Backtested over five years with consistently strong predictive accuracy. Ainvest brings institutional-grade artificial intelligence to everyday investors—transforming complexity into clarity with every score.
Holdings Analysis
Sector
Healthcare
100.00%
Healthcare
100.00%
Asset
Region

55.99%
28.99%
15.02%
Category
Ratio
North America
55.99%
Europe
28.99%
Asia
15.02%
Investment Style
No data is currently available
Top 10 Holdings
Symbol
Ratio
NVO
Novo Nordisk
17.10%
LLY
Eli Lilly
15.50%
Roche Holding AG
4.75%
Chugai Pharmaceutical Co Ltd
4.46%
GPCR
Structure
4.36%
PFE
Pfizer
4.33%
Ascletis Pharma Inc
4.15%
Hanmi Pharm Co Ltd
4.10%
AMGN
Amgen
4.09%
Zealand Pharma A/S
3.98%
Top 10 Weight 66.82%
26 Total Holdings
Is SPY better than OZEM?
Dividends
Dividend Payout History
Declaration Date | Record Date | Payment Date | Amount |
|---|---|---|---|
| 2025-12-30 | 2025-12-30 | 2025-12-31 | 0.410 |
| 2024-12-30 | 2024-12-30 | 2024-12-31 | 0.053 |
How Much Does OZEM Pay in Dividends?
Premium/Discount Chart
Assets Under Management
Should I buy OZEM?
Fund Flows
